Japan Tissue Engineering Co

Japan Tissue Engineering Co Depreciation & Amortization

The Depreciation & Amortization of Japan Tissue Engineering Co (7774.T) as of Nov 20, 2026 is 41.92 M JPY. In the previous year, Depreciation & Amortization was 23.85 M JPY — a change of 75.77% (higher).

Depreciation & Amortization

41.92 MJPY

YoY

75.77%

Last updated:

Depreciation & Amortization of Japan Tissue Engineering Co is 2025 41.92 M JPY. Depreciation & Amortization of Japan Tissue Engineering Co was 2024 23.85 M JPY. It decreases by 75.77% higher compared to the previous year.

The Japan Tissue Engineering Co Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2018
36.90 M JPY
Jan 1, 2019
21.73 M JPY
Jan 1, 2020
16.28 M JPY
Jan 1, 2021
19.88 M JPY
Jan 1, 2022
17.84 M JPY
Jan 1, 2023
21.35 M JPY
Jan 1, 2024
23.85 M JPY
Jan 1, 2025
41.92 M JPY
The Japan Tissue Engineering Co Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
41.92 MJPY+75.77%
23.85 MJPY+11.69%
21.35 MJPY+19.71%
17.84 MJPY-10.28%
19.88 MJPY+22.13%
16.28 MJPY-25.10%
21.73 MJPY-41.10%
36.90 MJPY+56.90%
23.52 MJPY-49.22%
46.31 MJPY+12.79%
41.06 MJPY-17.05%
49.50 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Japan Tissue Engineering Co Stock analysis

What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Japan Tissue Engineering Co stock

Depreciation & Amortization of Japan Tissue Engineering Co is 41.92 M JPY in 2025.

Depreciation & Amortization of Japan Tissue Engineering Co changed from 23.85 M JPY to 41.92 M JPY, representing a 75.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization Japan Tissue Engineering Co since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's Japan Tissue Engineering Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Japan Tissue Engineering Co

All Key Metrics — Japan Tissue Engineering Co